secwatch.observer — SEC 8-K summary
======================================

Issuer:     HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK:        0000818033
Form:       8-K
Filed at:   2026-06-02T21:15:12+00:00
Accession:  0001193125-26-253851
Event type: litigation
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Court invalidates two CINVANTI patents; Heron to appeal to Federal Circuit
--------------------------------------------------------------------------

- U.S. District Court for Delaware ruled claims of Patents 12,115,255 and 12,290,520 invalid on June 1, 2026.
- Decision does not affect prior settlements for CINVANTI or APONVIE injectable emulsions.
- Heron intends to appeal to the Federal Circuit, a court specializing in patent disputes.
- CEO Craig Collard said company will vigorously pursue appeal and all available remedies.
- Litigation with Azurity (formerly Slayback) involves a generic version of CINVANTI.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818033/000119312526253851/0001193125-26-253851-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818033/000119312526253851/hrtx-20260602.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-253851

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer